Charles River Laboratories (CRL) Tops Q2 EPS by 5c, beats revenue, offers guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $279.15 +2.10%
EPS Growth %: +21.8%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
ALZN, ASPU, USAU, More
EPS Growth %: +21.8%
Financial Fact:
Net income: 38.03M
Today's EPS Names:
ALZN, ASPU, USAU, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.69, $0.05 better than the analyst estimate of $2.64. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion.
GUIDANCE:
Charles River Laboratories sees FY2023 EPS of $10.30-$10.90.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Intuit holds investor day, reaffirms fiscal 2027 guidance
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
